Spondyloarthritis & psoriatic arthritis
Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching
Authors' conclusion
A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE vs LOE.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) in routine care, 12 European registriesTumor necrosis factor inhibitors (TNFi)-series
- Participants
- 8,254 vs 2,939
- Exposure
- Second vs third TNFi series; withdrawal from preceding TNFi due to adverse events (AE) vs lack of efficacy (LOE)
- Second TNFin = 8,254
- Third TNFin = 2,939
- Outcome
- 12-month drug retention and 6-month remission (ASDAS-ID)
Methodological detailspooled data from 12 European registries, routine care
- Pooled data from 12 European registries
- Routine care
Main finding
As reported in the abstract
12-month drug retention · 12 months
Observational data: associations, not effects.
Further findings
6-month ASDAS-ID rate
| Outcome | P value |
|---|---|
| 12-month drug retention on second TNFi, primary (LOE <26 weeks) vs secondary (LOE ≥26 weeks) non-responders | P < 0.001 |
| 6-month ASDAS-ID on second TNFi by withdrawal reason · 6 monthsAE vs LOE | P < 0.001 |
| 6-month ASDAS-ID on third TNFi by withdrawal reason · 6 monthsAE vs LOE | P = 0.20 |
- 12-month drug retention on second TNFi, primary (LOE <26 weeks) vs secondary (LOE ≥26 weeks) non-responders: Primary non-responders 58%
- 12-month drug retention on second TNFi, primary (LOE <26 weeks) vs secondary (LOE ≥26 weeks) non-responders: Secondary non-responders 71%
- 6-month ASDAS-ID on second TNFi by withdrawal reason: AE 27%
- 6-month ASDAS-ID on second TNFi by withdrawal reason: LOE 17%
- 6-month ASDAS-ID on third TNFi by withdrawal reason: AE 19%
- 6-month ASDAS-ID on third TNFi by withdrawal reason: LOE 13%
12-month drug retention by withdrawal reason (AE vs LOE)
- Second TNFi: AE 68% vs LOE 67%, similar
- Third TNFi: AE and LOE both 68%
Original publication
Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching. Rheumatology (Oxford). Published 20 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →